Patrick Walker, MD
Family Medicine · Denham Springs, LANPI 1245441658
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 914 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 48 manufacturers, the largest accounting for just 12.1% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 914 payments — averaging $16.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$2K
- AbbVie$2K
- Boehringer Ingelheim$1K
- AstraZeneca$1K
- Pfizer$1K
- Novo Nordisk$1K
- plus $7K from 42 others
What the payments were for
- Food & beverage$15,14799%
- Education$1781%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$355
- FARXIGA$174
- SYMBICORT$174
- CAPLYTA$114
- Kerendia$105
How this compares
$15,325 in reported general payments places this provider in the 95th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 233 | $250,627 |
| MounjaroTirzepatide | 171 | $206,192 |
| FarxigaDapagliflozin Propanediol | 127 | $126,286 |
| OzempicSemaglutide | 89 | $111,949 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 78 | $70,599 |
| VascepaIcosapent Ethyl | 81 | $59,235 |
| TrulicityDulaglutide | 20 | $37,261 |
| EliquisApixaban | 51 | $36,179 |
| VraylarCariprazine Hcl | 21 | $32,371 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 50 | $30,814 |
| BelsomraSuvorexant | 48 | $21,983 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 27 | $21,837 |
| MyrbetriqMirabegron | 33 | $20,811 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $18,442 |
| XareltoRivaroxaban | 12 | $18,175 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Stiolto Respimat | $1,372 | $272,464260 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,850 | $243,452191 claims |
| AstraZenecaFarxiga, Symbicort | $1,339 | $132,715138 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $1,044 | $122,548164 claims |
| Novo NordiskOzempic | $1,074 | $111,94989 claims |
| AbbVieVraylar, Linzess, Synthroid | $1,610 | $45,47460 claims |
| PfizerEliquis | $1,331 | $36,17951 claims |
| MerckBelsomra, Dulera | $237 | $26,01059 claims |
| Astellas Pharma US IncMyrbetriq | $144 | $20,81133 claims |
| Johnson & JohnsonXarelto | $551 | $18,17512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Denham Springs
- April McCullohDenham Springs$25K
- Durwin WalkerDenham Springs$16K
- Robin DaleDenham Springs$12K
- Christine SmithBaton Rouge$185K
- Thomas DansbyMonroe$169K
- Michael FlemingShreveport$165K
- Robert St AmantGonzales$156K
- William HathawaySpringhill$105K
- Cesar GonzalesWest Monroe$94K
- Phillip ConnerSulphur$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.